5

10





- 48 -

WHAT IS CLAIMED IS:

- 1. A method for treating virus infection comprising the step of administering to a subject in need thereof an anti-viral amount of a leflunomide product.
- 2. The method of claim 1 wherein the eflunomide product is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide (HWA 486).
 - 3. The method of claim 1 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (A771726).
 - 4. The method of claim 1 wherein the amount of leflunomide product administered is from about 0.1 to 80 mg/day.
 - 5. The method of claim 1 wherein the virus is a herpesvirus.
 - 6. The method of claim 5 wherein the virus is selected from the group consisting of paramyxoviruses, picornaviruses and hepatitis viruses.
- 7. The method of claim 1 wherein the virus is selected from the group consisting of CMV, HSV, measles virus, rhinoviruses, hepatitis B and hepatitis C.
 - 8. The method of claim 1 wherein another anti-viral agent is administered to the subject.
- 9. The method of claim 1 wherein a pyrimidine is administered to the subject.

10

15

- 49 -

- 10. The method of claim 1 wherein the virus is resistant to antiviral agents that inhibit viral DNA replication.
- 11. The method of claim 1 wherein the subject is at risk of viral infection.
- 5 12. The method of claim, wherein the subject is suffering from virus infection.
 - 13. A method of inhibiting growth of a virus in a cell comprising the step of contacting the cell with an amount of leflunomide product effective to inhibit virion assembly.
 - 14. A method of screening for a leflunomide product or derivative thereof having anti-viral activity comprising the steps of:
 - (a) growing a virus in cell culture,
 - (b) contacting the cell culture with a test amount of leflunomide product or derivative thereof, and
 - (c) determining the effect of the test amount on viral growth.
 - 15. Use of a leflunomide product in the preparation of a medicament for treatment of viral infection.

